Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by Valuehunter72on Jun 29, 2020 9:39pm
188 Views
Post# 31205858

Share count Offering. Then and Now

Share count Offering. Then and Now

A month ago....here is the verbiage.

Vaxil Bio Ltd. has engaged M Partners Inc. as lead agent and sole bookrunner to sell, by way of private placement, on a commercially reasonable efforts basis, up to 35,294,118 units of the company at a price of 8.5 cents per unit to for aggregate gross proceeds of up to $3-million, subject to the company's receipt of minimum gross proceeds of $2-million or 23,529,412 units of the company.

The company has also granted the agents an option exercisable for the sale of up to an additional 15 per cent of the units sold under the offering, to cover overallotments, if any.
 

On the closing of the offering, the company has agreed to pay the agents a cash commission of up to 7 per cent of the gross proceeds of the offering and non-transferable warrants of up to 7 per cent of the aggregate number of units issued pursuant to the offering exercisable for the purchase of units at 8.5 cents per unit for a period of three years following the closing of the offering.

Math....

maximum 35,294,118 shares to raise the 3 million.

add a 15% overage ...equals 5,294,117

Total 40, 588,235 shares (double this with warrant shares at 13 cents)

Now....add 7% 2,841,176 shares for MPartner warrants


 

Todays numbers

 

VAXIL ANNOUNCES PRIVATE PLACEMENT EXTENSION

Vaxil Bio Ltd. has provided an update on its previously announced brokered private placement of up to 58,823,530 units of the company with minimum gross proceeds of $2-million, with M Partners Inc. as lead agent. The Offering remains in progress and the closing date has been extended and is expected to occur on or about July 17, 2020. Further details of the Offering are included in the Company's press release from May 26, 2020.

 

So for whatever reason Vaxil decides they need more cash and have increased the number of shares offered dramatically.

Obviously they were oversubscribed and decided to increase the offering.  


If you multiply the new amount of shares by .085 cents....you get 5 million dollars...and 5 cents.

Vaxil already has 1.45 million in the bank.....needs another 5 million.

Strategic Innovation Fund will match your contribution.....

5 million turns to 10 million for Phase 1

force the 59 million warrants to be cashed in should the price hold above 26 cents for 10 consecutive days....59 million warrant shares times 13 cents...is 

$7,680,000.....Strategic Innovation fund matches that...Vaxil has over $15 million for following rounds of clinical trials.


https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/clntSmmry?clientOrgCorpNumber=366563&sMdKy=1590856256498&V_TOKEN=1590856256498

 

 

Experience shows that the government's share of funding for a given project usually varies from 10% of project costs up to 50% in exceptional cases.

SIF funding is project-based where a portion of eligible project costs are reimbursed. Potential applicants are encouraged to base the level of funding sought on the needs of their project and not automatically seek 50% funding in all cases.
 

https://www.ic.gc.ca/eic/site/125.nsf/eng/00001.html
 


Looking to load some cheap shares as some nervous nellies are looking at getting out.

Do your own DD


 


 

<< Previous
Bullboard Posts
Next >>